CD14 Cancer Research Results

CD14, CD14: Click to Expand ⟱
Source:
Type:
CD14 is a co-receptor that recognizes several ligands, including bacterial lipopolysaccharide (LPS) and other pathogen-associated molecular patterns (PAMPs). It plays a pivotal role in innate immunity by identifying danger signals.
CD14 works in close cooperation with Toll-like receptors (TLRs), especially TLR4.

CD14 is highly expressed in myeloid cells within the tumor microenvironment, such as tumor-associated macrophages (TAMs) and certain dendritic cell subsets.
A high prevalence of CD14⁺ cells within the tumor microenvironment is associated with chronic inflammation, which in turn can contribute to tumor progression, angiogenesis, and eventual metastasis.
Scientific Papers found: Click to Expand⟱
6750- DHA,  Chemo,    Docosahexaenoic acid (DHA) supplementation attenuates changes in the concentration, phenotype, and response of immune peripheral blood cells in breast cancer patients undergoing neoadjuvant therapy. Secondary findings from the DHA-WIN trial
- Trial, BC, NA
*CD14↑, In the placebo group the proportion of T cells (CD3 +), and functionally active monocytes (CD14 + HLA-DR +) was reduced at the last cycle of chemotherapy (15 weeks) but remained constant in the DHA group
*NLR↓, The neutrophil-to-lymphocyte ratio (NLR) was maintained in the DHA group but increased in the placebo at the end of chemotherapy
eff↑, An increase in this ratio was associated with lower chance of achieving pathological complete response
*IL4↑, After 15 weeks of therapy, the DHA-supplemented group had higher concentrations of stimulated cytokines IL-4, IL-10, and the T helper type 1 cytokine IFN-γ after phytohemagglutinin (PHA) challenge, and higher concentrations of TNF-α and IFN-γ cytokin
*IL10↑,
*IFN-γ↑,
*TNF-α↑,
Imm↑, Supplementing DHA during breast cancer neoadjuvant chemotherapy improved systemic immune function by attenuating changes in blood cell concentrations, preventing depletion of immune cells
eff↑, Newell et al. [19] previously demonstrated an improvement in chemotherapy success, measured as reduced tumor weight and Ki67 activity (proliferation) in animals fed DHA (3.9% w/w of total fat) in combination with chemotherapy (docetaxel) i
TumW↓,

1345- SK,    The Critical Role of Redox Homeostasis in Shikonin-Induced HL-60 Cell Differentiation via Unique Modulation of the Nrf2/ARE Pathway
- in-vitro, AML, HL-60
CD14↑,
CD11b↑,
ROS↑, Shikonin result in the predominance of cell death because the oxidative stress is more severe and overcome the antioxidative capacity of Nrf2/ARE pathway, resulting in cell death.
GSH↓,
GSH/GSSG↓,
GPx↑, mRNA expression levels of GPX and CAT were markedly upregulated by Shikonin in a dose-dependent manner
Catalase↓, Shikonin causes apoptosis in human glioma cells by interrupting intracellular redox homeostasis, which included CAT downregulation
Diff↑, Shikonin-induced HL-60 cell differentiation


Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↓, 1,   GPx↑, 1,   GSH↓, 1,   GSH/GSSG↓, 1,   ROS↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Diff↑, 1,  

Migration(tgid=13) ⓘ

CD11b↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD14↑, 1,   Imm↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↑, 2,  

Functional Outcomes(tgid=23) ⓘ

TumW↓, 1,  
Total Targets: 11

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

NLR↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD14↑, 1,   IFN-γ↑, 1,   IL10↑, 1,   IL4↑, 1,   TNF-α↑, 1,  
Total Targets: 6

Scientific Paper Hit Count for: CD14, CD14
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1068  State#:%  Dir#:2
  wNotes=on  sortOrder:rid,rpid

 

Home Page